BCEL

Atreca, Inc. (BCEL) | Rumor.io

Atreca

BCEL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% new

Jan 30

$BCEL is expected to push past $0.39 tomorrow, with some traders anticipating a potential 3x return.
A double bottom formation has been identified in $BCEL, potentially indicating a reversal in price movement.
$BCEL has seen a 7% increase in value since a recent mention, with some traders speculating on its potential for further growth.

Generated by AI

Sentiment

Of the messages about BCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100%
Bearish	—	—	—	0%

Bullish· Jan 29

$BCEL is expected to break above $0.34 and hold on a 15-minute candle for a potential run to $0.44.
The TTE flow indicator shows bulls in control, allowing for a long position, and the algo has 79 wins out of 100 trades taken.
$BCEL is seen as a potential multi-day runner on good Fed news, with a target of $0.40 or more.

Bearish· Jan 12

$BCEL's short sellers are struggling to break the stock, suggesting a possible reversal in bearish momentum.
The stock's price is likely to reject previous resistance levels, potentially leading to a decline in value.
Sellers are "fucking it up" and shorts are "burning in hell", indicating a strong bearish sentiment and potential for significant losses.

Generated by AI

Topics

Of the messages about BCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Mar 30

Atreca, Inc. (BCEL) released its Q4 2022 earnings call transcript, providing insights into the company's performance.
Evercore has given Atreca, Inc. (BCEL) an outperform rating, indicating a positive outlook on the company's future prospects.
These developments suggest that investors and analysts are closely watching Atreca, Inc. (BCEL) for potential growth opportunities.

Technical Analysis· Jan 12

$BCEL has formed an inverse head and shoulders, a bullish pattern, and is due for a pullback to retest previous highs.
A break above $0.4790 could trigger a move to $0.6146, with further resistance at $0.6589 and $0.75, while a failure to break this level could lead to a decline.
The stock has been showing signs of a possible top, with multiple topping tails in a row just below recent highs, and is at a critical area where a large red candle could flash.

Generated by AI

Community

Of the messages about BCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	28.26%
Newcomers	—	—	100%	71.74%

Regulars· Jul 29

Atreca's stock price has declined due to the presentation of early-stage data from a Phase 1b trial of ATRC-101, which showed limited efficacy in treating select advanced solid tumors.
The initial clinical data from the Phase 1b trial of ATRC-101 showed that the most common adverse events were respiratory failure and sepsis.
Atreca's stock price has hit a new 52-week low, with the current price at $5.35, a decline of -33.00% from the previous day.

Newcomers· Oct 12

New investors are focusing on the potential for Atreca, Inc. ($BCEL) to be the next big thing, comparing it to other stocks like $GLG.
Some newcomers are trying to make sense of the company's leadership structure, pointing out the CEO's involvement with another company ($TPST).
Others are trying to understand the stock's performance, with some setting specific price targets ($0.31, $0.40) and risk levels (Medium).

Generated by AI

Also Discussed

Investors talking about BCEL also mention

#	Name	Attention
1	IGMS - IGM Biosciences, Inc.	——
2	Alector Inc.ALEC	0%new
3	HOOK - HOOKIPA Pharma Inc.	——
4	RedHill Biopharma Ltd. American Depositary SharesRDHL	0%0
5	The Marygold Companies, Inc.MGLD	0%+0
6	AONC - American Oncology Network, Inc.	——
7	SPEC - Spectaire Holdings Inc.	——
8	GFOR - Graf Acquisition Corp. IV	——
9	noco-noco Inc.NCNC	0%0
10	FRBN - Forbion European Acquisition Corp.	——

Atreca, Inc.

Location

Social

What share of all stock conversation is about BCEL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% +0	0% new

Jan 30

$BCEL is expected to push past $0.39 tomorrow, with some traders anticipating a potential 3x return.
A double bottom formation has been identified in $BCEL, potentially indicating a reversal in price movement.
$BCEL has seen a 7% increase in value since a recent mention, with some traders speculating on its potential for further growth.

Generated by AI

Sentiment

Of the messages about BCEL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100%
Bearish	—	—	—	0%

Bullish· Jan 29

$BCEL is expected to break above $0.34 and hold on a 15-minute candle for a potential run to $0.44.
The TTE flow indicator shows bulls in control, allowing for a long position, and the algo has 79 wins out of 100 trades taken.
$BCEL is seen as a potential multi-day runner on good Fed news, with a target of $0.40 or more.

Bearish· Jan 12

$BCEL's short sellers are struggling to break the stock, suggesting a possible reversal in bearish momentum.
The stock's price is likely to reject previous resistance levels, potentially leading to a decline in value.
Sellers are "fucking it up" and shorts are "burning in hell", indicating a strong bearish sentiment and potential for significant losses.

Generated by AI

Topics

Of the messages about BCEL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	100%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	0%

Announcements· Mar 30

Atreca, Inc. (BCEL) released its Q4 2022 earnings call transcript, providing insights into the company's performance.
Evercore has given Atreca, Inc. (BCEL) an outperform rating, indicating a positive outlook on the company's future prospects.
These developments suggest that investors and analysts are closely watching Atreca, Inc. (BCEL) for potential growth opportunities.

Technical Analysis· Jan 12

$BCEL has formed an inverse head and shoulders, a bullish pattern, and is due for a pullback to retest previous highs.
A break above $0.4790 could trigger a move to $0.6146, with further resistance at $0.6589 and $0.75, while a failure to break this level could lead to a decline.
The stock has been showing signs of a possible top, with multiple topping tails in a row just below recent highs, and is at a critical area where a large red candle could flash.

Generated by AI

Community

Of the messages about BCEL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	28.26%
Newcomers	—	—	100%	71.74%

Regulars· Jul 29

Atreca's stock price has declined due to the presentation of early-stage data from a Phase 1b trial of ATRC-101, which showed limited efficacy in treating select advanced solid tumors.
The initial clinical data from the Phase 1b trial of ATRC-101 showed that the most common adverse events were respiratory failure and sepsis.
Atreca's stock price has hit a new 52-week low, with the current price at $5.35, a decline of -33.00% from the previous day.

Newcomers· Oct 12

New investors are focusing on the potential for Atreca, Inc. ($BCEL) to be the next big thing, comparing it to other stocks like $GLG.
Some newcomers are trying to make sense of the company's leadership structure, pointing out the CEO's involvement with another company ($TPST).
Others are trying to understand the stock's performance, with some setting specific price targets ($0.31, $0.40) and risk levels (Medium).

Generated by AI

Atreca

Social

Jan 30

Sentiment

Bullish· Jan 29

Bearish· Jan 12

Topics

Announcements· Mar 30

Technical Analysis· Jan 12

Community

Regulars· Jul 29

Newcomers· Oct 12

Also Discussed

Atreca, Inc.

Company Information

Location

Also Discussed

Social

Jan 30

Sentiment

Bullish· Jan 29

Bearish· Jan 12

Topics

Announcements· Mar 30

Technical Analysis· Jan 12

Community

Regulars· Jul 29

Newcomers· Oct 12